Study information |
Patients included in study | 415 | |
Patients excluded due to no lung ultrasound film clips available analysis | 17 | |
Patients analysed | 398 | 96 |
Site 1 | 201 | 50.5 |
Site 2 | 82 | 20.6 |
Site 3 | 69 | 17.3 |
Site 4 | 46 | 11.6 |
Demographics |
Age years | 387 | 67.8±15.8 |
Weight kg | 242 | 78.4±19.7 |
Height cm | 246 | 171.6±10.1 |
Sex, female | 398 | 189 (47.5) |
Clinical data |
Systolic blood pressure mmHg | 386 | 130.7±22.0 |
Diastolic blood pressure mmHg | 383 | 74.5±13.5 |
Peripheral oxygen saturation % | 387 | 95.3±3.3 |
Heart rate beats·min−1 | 381 | 85.1±18.4 |
Respiratory frequency breaths·min−1 | 386 | 20.3±5.1 |
Supplementary oxygen doses L·min−1 | 364 | 1.7±3.3 |
Biochemical data | | |
Ferritin μg·L−1 | 175 | 986.0±1183.6 |
Haemoglobin mmol·L−1 | 384 | 7.7±1.4 |
C-reactive protein mg·L−1 | 381 | 64±66 |
Leukocytes, count ×109 L−1 | 385 | 9.0±5.1 |
Lymphocytes, count ×109 L−1 | 374 | 1.4±1.3 |
Monocytes, count ×109 L−1 | 299 | 0.6±0.4 |
Neutrophils, count ×109 L−1 | 379 | 6.7±4.6 |
Estimated glomerular filtration rate mL·min−1 | 272 | 69.6±23.3 |
Carbamide mmol·L−1 | 291 | 7.2±5.8 |
Creatinine μmol·L−1 | 385 | 98.0±92.3 |
Natrium mmol·L−1 | 385 | 138.5±4.2 |
Potassium mmol·L−1 | 382 | 3.8±0.5 |
Fibrin D-dimer mg·L−1 (FEU) | 263 | 2.4±4.6 |
Pro-brain natriuretic peptide ng·L−1 | 155 | 706.4±2418.1 |
Troponin I (HS) ng·L−1 | 75 | 211.0±1120.1 |
Troponin T (HS) ng·L−1 | 93 | 68.9±349.1 |
Glucose mmol·L−1 | 249 | 7.4±3.0 |
Haemoglobin A1c mmol·mol−1 | 160 | 44.5±13.2 |
pH-arterial | 301 | 7.5±0.1 |
PaCO2 kPa | 297 | 5.0±1.3 |
PaO2 kPa | 132 | 10.2±3.1 |
Base excess mmol·L−1 | 133 | 1.3±4.8 |
Hydrogen carbonate mmol·L−1 | 300 | 25.2±4.7 |
Lactate-arterial mmol·L−1 | 275 | 1.5±0.9 |
Ultrasound equipment | | |
General Electric's Vivid S60 | 398 | 201 (51) |
General Electric's LogiQ S8 | 398 | 151 (38) |
Sonosite X-porte | 398 | 46 (12) |
Phased array transducer with cardiography pre-set | 398 | 201 (51) |
Curvilinear transducer with abdominal pre-set | 398 | 197 (49) |
Outcome data | | |
COVID-19 positive PCR test | 398 | 227 (57) |
Overall mortality 30 days after admission | 398 | 47 (11.8) |
COVID-19-related mortality 30 days after admission | 398 | 28 (7) |
Admission to intensive care | 398 | 21 (5.3) |
COVID-19-positive admission to intensive care | 398 | 19 (4.8) |
Ventilator treatment | 398 | 18 (4.9) |
COVID-19-positive ventilator treatment care | 398 | 17 (4.3) |
High-flow oxygen treatment | 398 | 56 (14) |
COVID-19-positive, high-flow oxygen treatment | 398 | 51 (12.8) |
Nasal oxygen treatment | 398 | 159 (43.3) |
COVID-19-positive, nasal oxygen treatment | 398 | 117 (29.4) |